...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >A Monitored-Release Study of Methrazone in General Practice
【24h】

A Monitored-Release Study of Methrazone in General Practice

机译：在常规实践中甲乙酮的监测释放研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Methrazone, a non-steroidal anti-inflammatory drug, was used on a monitored release study in general practice to treat 2,693 patients with rheumatoid or osteoarthritis. In a dose of 200 mg three times daily, it appeared to produce clear benefit in between 50% and 60% of patients. Adverse reactions such as dyspepsia and skin rash led to the drug being withdrawn in 11% of patients. There were three major adverse reactions possibly due to the drug (haematemesis, rectal bleeding and acute purpura), but no cases of severe leucopenia or thrombocytopenia. Methrazone is a useful anti-inflammatory agent. In particular, it is unlikely to cause interactions with other drugs, including cardiac glycosides such as digoxin.
机译：美沙酮是一种非甾体类抗炎药，通常用于监测释放研究，以治疗2693名类风湿或骨关节炎患者。每天三剂200 mg的剂量似乎在50％至60％的患者中产生明显的益处。消化不良和皮疹等不良反应导致11％的患者撤药。该药可能引起三种主要不良反应（呕血，直肠出血和急性紫癜），但没有严重的白细胞减少症或血小板减少症的病例。甲raz酮是一种有用的抗炎药。特别是，它不太可能引起与其他药物的相互作用，包括强心苷等强心苷。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号